A5069527691- Bone health and treatments
- Geriatric Care and Nursing Homes
- Radiopharmaceutical Chemistry and Applications
- Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Cancer, Stress, Anesthesia, and Immune Response
- Clinical Nutrition and Gastroenterology
- Estrogen and related hormone effects
- Colorectal Cancer Surgical Treatments
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Palliative Care and End-of-Life Issues
- Breast Implant and Reconstruction
- Abdominal vascular conditions and treatments
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Health disparities and outcomes
- Intensive Care Unit Cognitive Disorders
- Drug-Induced Ocular Toxicity
- Family Support in Illness
- Abdominal Trauma and Injuries
- Social Media in Health Education
- Surgical site infection prevention
- Immune Cell Function and Interaction
Western University
2023
University of Windsor
2023
Ottawa Hospital Research Institute
2018-2022
Ottawa Hospital
2018-2022
Bruyère
2022
University of Ottawa
2019-2020
Surgical stress results in a significant reduction natural killer (NK) cell cytotoxicity (NKC), which has been linked to postoperative cancer metastases. However, few studies have measured the impact of surgical upon NK IFNγ secretion (NKA), cytokine with essential roles controlling infection and The objective this study was investigate on NKA colorectal (CRC) surgery patients.Peripheral blood collected from CRC patients (n = 42) preoperatively day (POD) 1, 3, 5, 28, 56. Healthy donor 27)...
BackgroundOptimal dosing of bone-targeted agents (BTAs), in patients with bone metastases remains an important clinical question. This trial compared 4-weekly versus 12-weekly therapy.Patients and methodsPatients from breast or castration-resistant prostate cancer (CRPC), who were going to start already on BTAs, randomised 1:1 BTA treatment for one year. Primary end point was change health-related quality life (HRQoL)-physical function European Organisation Research Treatment Cancer...
Background: The effectiveness of different acellular dermal matrices (ADM) used for implant-based reconstruction immediately following mastectomy is an important clinical question. A prospective randomized trial was performed to evaluate the superiority DermACELL over Alloderm-RTU in reducing drain duration. Methods: Patients undergoing with subpectoral immediate and permanent breast were or DermACELL. primary outcome seroma formation, measured by duration postoperative placement. Secondary...
11501 Background: Defining the optimal dosing interval of commonly used bone-targeted agents (BTAs), such as denosumab and bisphosphonates, for patients with bone metastases remains an important clinical question. We performed a pragmatic randomised trial comparing non-inferiority 12- versus 4-weekly BTAs in from breast prostate cancer. Methods: Patients metastases, who were either BTA-naïve, or already receiving, denosumab, pamidronate zoledronate eligible. They to receive their chosen BTA...
Introduction Despite 40 randomised controlled trials (RCTs) investigating preoperative oral antibiotics (OA) and mechanical bowel preparation (MBP) to reduce surgical site infection (SSI) rate following colon surgery, there has never been an RCT published comparing OA alone versus no preparation. Of the four possible regimens (OA alone, MBP plus preparation), evidence is conflicting for studied groups. Furthermore, guidelines vary, with recommendations or The National Surgical Quality...
A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly 4 133) BTA dosing for metastatic breast and castration-resistant prostate (CRPC) cancer. Using a decision tree model, we calculated treatment symptomatic skeletal event (SSE) costs as well quality-adjusted life-years (QALYs) each option. Deterministic probabilistic sensitivity analyses were to...
Abstract Background: Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in DNA damage repair. Tumors with Damage Response (DDR) defects exhibit increased susceptibility to drugs targeting PARP. The induce like Irinotecan (a Topoisomerase I inhibitor) are widely used clinic as well. However, intrinsic resistance remains significant obstacle, leading frequent treatment failures. Chk2 is activated response these inducing agents and hold the cell cycle. We developed pre-IND candidate...
Technology has changed the way medicine is practiced. This commentary considers effect of digital communications and offers advice on e‐mail etiquette.
e24083 Background: Randomized clinical trials evaluated bone modifying agents (BMAs) such as bisphosphonates and denosumab for metastases 1-2 years in duration even though BMA therapy is commonly administered much longer. A systematic review on the risk-benefit of continuing BMAs longer than 2 breast cancer or castrate-resistant prostate was conducted. Methods: Medline, Embase Cochrane Register Controlled Trials were searched (1970 - February 2019) randomized studies, observational case...